{
  "company": {
    "name": "Oak Hill Bio",
    "website": "https://oakhillbio.com/",
    "record": "https://startuphistory.org/c/oakhillbio.com"
  },
  "status": null,
  "history_since": "2022-02-03T11:57:28.000Z",
  "baseline": {
    "snapshot_id": "a714b41d8869645f5a18be520a41ef59f22f71645f2f0806201a27fb03f4e2c9",
    "observed_at": "2022-02-03T11:57:28.000Z",
    "headline": "Oak Hill Bio is committed to developing life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases.",
    "description": null,
    "evidence": "https://web.archive.org/web/20220203115728/https://www.oakhillbio.com/",
    "evidence_kind": "internet_archive",
    "facts": null,
    "basis": "first_observation",
    "is_change": false
  },
  "live_captures": 1,
  "last_checked": "2026-11-06T17:51:04.010Z",
  "live_status": null,
  "messaging": [
    {
      "quote_observed_at": "2025-01-08T21:25:55.000Z",
      "variants": [
        {
          "headline": "Oak Hill Bio is committed to developing life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases.",
          "subhead": null,
          "observed_at": "2022-02-03T11:57:28.000Z",
          "evidence": "https://web.archive.org/web/20220203115728/https://www.oakhillbio.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Oak Hill Bio is committed to developing life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases.",
          "subhead": null,
          "observed_at": "2023-03-06T05:00:01.000Z",
          "evidence": "https://web.archive.org/web/20230306050001/https://www.oakhillbio.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Oak Hill Bio is committed to developing life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases.",
          "subhead": null,
          "observed_at": "2023-09-26T21:19:17.000Z",
          "evidence": "https://web.archive.org/web/20230926211917/https://www.oakhillbio.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Oak Hill Bio is committed to developing life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases.",
          "subhead": null,
          "observed_at": "2024-01-04T10:26:55.000Z",
          "evidence": "https://web.archive.org/web/20240104102655/https://www.oakhillbio.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Oak Hill Bio is committed to developing life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases.",
          "subhead": null,
          "observed_at": "2024-07-07T08:07:07.000Z",
          "evidence": "https://web.archive.org/web/20240707080707/https://www.oakhillbio.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Oak Hill Bio is committed to developing life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases.",
          "subhead": null,
          "observed_at": "2025-01-08T21:25:55.000Z",
          "evidence": "https://web.archive.org/web/20250108212555/https://www.oakhillbio.com/",
          "evidence_kind": "internet_archive"
        }
      ],
      "headline": "Oak Hill Bio is committed to developing life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases.",
      "subhead": null,
      "from": "2022-02-03T11:57:28.000Z",
      "to": "2025-01-08T21:25:55.000Z",
      "captures": 6,
      "evidence": "https://web.archive.org/web/20250108212555/https://www.oakhillbio.com/",
      "evidence_kind": "internet_archive",
      "seen": {
        "between": {
          "from": "2022-02-03T11:57:28.000Z",
          "to": "2025-01-08T21:25:55.000Z"
        }
      },
      "current": false
    },
    {
      "quote_observed_at": "2026-11-06T17:51:04.010Z",
      "variants": [
        {
          "headline": "Advancing Rare Disease Therapies Across the Finish Line",
          "subhead": "Oak Hill Bio Ltd is a clinical-stage biotechnology company focused on acquiring and developing life-changing rare disease therapeutics. The company’s pipeline includes three programs in late-stage cli",
          "observed_at": "2025-07-21T07:36:38.000Z",
          "evidence": "https://web.archive.org/web/20250721073638/https://www.oakhillbio.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Advancing Rare Disease Therapies Across the Finish Line",
          "subhead": "Oak Hill Bio Ltd is a clinical-stage biotechnology company focused on acquiring and developing life-changing rare disease therapeutics. The company’s pipeline includes three programs in late-stage cli",
          "observed_at": "2026-01-19T11:33:51.000Z",
          "evidence": "https://web.archive.org/web/20260119113351/https://oakhillbio.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Advancing Rare Disease Therapies Across the Finish Line",
          "subhead": "Oak Hill Bio Ltd is a clinical-stage biotechnology company focused on acquiring and developing life-changing rare disease therapeutics. The company’s pipeline includes three programs in late-stage cli",
          "observed_at": "2026-07-12T12:04:59.000Z",
          "evidence": "https://web.archive.org/web/20260712120459/https://www.oakhillbio.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Advancing Rare Disease Therapies Across the Finish Line",
          "subhead": "Oak Hill Bio is a clinical-stage biotechnology company focused on acquiring and developing outstanding rare disease drugs that have been deprioritized by big pharma. The company's lead program is rugo",
          "observed_at": "2026-11-06T17:51:04.010Z",
          "evidence": "https://www.oakhillbio.com/",
          "evidence_kind": "live_capture"
        }
      ],
      "headline": "Advancing Rare Disease Therapies Across the Finish Line",
      "subhead": "Oak Hill Bio is a clinical-stage biotechnology company focused on acquiring and developing outstanding rare disease drugs that have been deprioritized by big pharma. The company's lead program is rugo",
      "from": "2025-07-21T07:36:38.000Z",
      "to": "2026-11-06T17:51:04.010Z",
      "captures": 4,
      "evidence": "https://www.oakhillbio.com/",
      "evidence_kind": "live_capture",
      "seen": {
        "between": {
          "from": "2025-07-21T07:36:38.000Z",
          "to": "2026-11-06T17:51:04.010Z"
        }
      },
      "current": true
    }
  ],
  "changes": [
    {
      "n": 1,
      "id": "page-a714b41d8869645f5a18be520a41ef59f22f71645f2f0806201a27fb03f4e2c9:9560d4f04c1d3c6f8e23f3613ae38f4be2c658ab9bfe338ea9daf2efe0458229:logos:40e97d6ef2a4d21f",
      "before_evidence": "https://web.archive.org/web/20220203115728/https://www.oakhillbio.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "logos",
      "label": "New logos",
      "summary": "Added logos to its homepage: Tauhid Ali, Ph.D., Josh Distler, J.D., Mark McHale, Ph.D., Victoria Niklas, M.A., M.D., Suki Malhi, Ph.D., David Rich, MPhil, Caitlin Clunie-O’Connor, D.Phil., Rachel Smith and 2 more.",
      "between": {
        "from": "2022-02-03T11:57:28.000Z",
        "to": "2023-03-06T05:00:01.000Z"
      },
      "evidence": "https://web.archive.org/web/20230306050001/https://www.oakhillbio.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": null
    },
    {
      "n": 2,
      "id": "page-9560d4f04c1d3c6f8e23f3613ae38f4be2c658ab9bfe338ea9daf2efe0458229:1fac49b5715ed8e19a74d1eb296c549658fd3d2d5d7da77c66c16b1eae171d2e:logos:35da54046da8ab48",
      "before_evidence": "https://web.archive.org/web/20230306050001/https://www.oakhillbio.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "logos",
      "label": "New logos",
      "summary": "Added logos to its homepage: Ike Greenstein, M.B.A., David Colpman, Daniel Curran, M.D. and Ramy Farid, Ph.D..",
      "between": {
        "from": "2023-03-06T05:00:01.000Z",
        "to": "2023-09-26T21:19:17.000Z"
      },
      "evidence": "https://web.archive.org/web/20230926211917/https://www.oakhillbio.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": null
    },
    {
      "n": 3,
      "id": "page-69cbb391381fac0304d9e797b79c845159d97c2321c0d526d6c0f2d5c9271098:418747638781139d6290cb2566501f25a7d4fd95aadd2a3aae110669f3bc2000:logos:4d3139d26fb7dadb",
      "before_evidence": "https://web.archive.org/web/20240104102655/https://www.oakhillbio.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "logos",
      "label": "New logos",
      "summary": "Added logos to its homepage: Sharon Morriss, Ph.D., Sacha Mann, Shashi Borade, Ph.D. and Kim Davis, J.D..",
      "between": {
        "from": "2024-01-04T10:26:55.000Z",
        "to": "2024-07-07T08:07:07.000Z"
      },
      "evidence": "https://web.archive.org/web/20240707080707/https://www.oakhillbio.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": null
    },
    {
      "n": 4,
      "id": "page-418747638781139d6290cb2566501f25a7d4fd95aadd2a3aae110669f3bc2000:1cf741da55f6e2c6bed38326e1cf1c9b73527989926dc19ab334c58e616382f4:logos:7e88aa3df4f891c4",
      "before_evidence": "https://web.archive.org/web/20240707080707/https://www.oakhillbio.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "logos",
      "label": "New logos",
      "summary": "Added logos to its homepage: Jiaping Gu, Ph.D. and Hussein Al-Mossawi, Ph.D..",
      "between": {
        "from": "2024-07-07T08:07:07.000Z",
        "to": "2025-01-08T21:25:55.000Z"
      },
      "evidence": "https://web.archive.org/web/20250108212555/https://www.oakhillbio.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": null
    },
    {
      "n": 5,
      "id": "classifier-1cf741da55f6e2c6bed38326e1cf1c9b73527989926dc19ab334c58e616382f4:e5794570181d9dc6dd0e35a409f3105698e5b5d1df7e50be6481ec8379b0f869:repositioning",
      "before_evidence": "https://web.archive.org/web/20250108212555/https://www.oakhillbio.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "repositioning",
      "label": "Messaging",
      "summary": "Changed its homepage headline from “Oak Hill Bio is committed to developing life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune…” to “Advancing Rare Disease Therapies Across the Finish Line”.",
      "between": {
        "from": "2025-01-08T21:25:55.000Z",
        "to": "2025-07-21T07:36:38.000Z"
      },
      "evidence": "https://web.archive.org/web/20250721073638/https://www.oakhillbio.com/",
      "evidence_kind": "internet_archive",
      "basis": "classifier",
      "topic": "https://startuphistory.org/t/repositioned"
    }
  ],
  "update": null,
  "method": {
    "version": "messaging-v1",
    "description": "https://startuphistory.org/method"
  },
  "license": "CC-BY-4.0",
  "cite": "StartupHistory, “Oak Hill Bio” company record, https://startuphistory.org/c/oakhillbio.com"
}